Literature DB >> 19252814

RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro.

Kazushi Takayama1, Akinobu Suzuki, Tomoya Manaka, Susumu Taguchi, Yusuke Hashimoto, Yuuki Imai, Shigeyuki Wakitani, Kunio Takaoka.   

Abstract

Noggin is a major extracellular antagonist to bone morphogenetic proteins (BMPs) which binds to BMPs and blocks binding of them to BMP-specific receptors and negatively regulates BMP-induced osteoblastic differentiation. In this study, we investigated the effect of noggin silencing by transfection of small interfering RNA (siRNA) on BMP-induced osteoblastic differentiation in vitro and ectopic bone formation in vivo induced by recombinant human BMP-2 (rhBMP-2). Noggin mRNA expression was up-regulated in response to rhBMP-2 in C2C12 cells, a myoblastic cell line, in dose- and time-dependent fashion as determined by real-time RT-PCR assay. Silencing of noggin expression by transfection of noggin siRNA suppressed BMP-stimulated noggin expression, resulting in acceleration of BMP-induced osteoblastic differentiation. For in vivo noggin silencing, siRNA was injected locally into back muscles and transfected into local cells by electroporation, where rhBMP-2-retaining (5 microg) collagen disks had been surgically placed. The implants were harvested at 2 weeks after surgery from experimental and control group mice and analyzed by radiological and histological methods. As a result, bone mineral content of ossicles ectopically induced by rhBMP-2 was significantly increased by silencing of noggin. Our findings suggest that silencing of noggin enhances the osteoblastic differentiation of BMP-responding cells in vitro and new bone formation induced by rhBMP-2 in vivo by eliminating negative regulation of the effects of BMP. RNA interference might be useful for intensifying the effects of BMP in promoting new bone (callus) formation in repair of damaged bone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252814     DOI: 10.1007/s00774-009-0054-x

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  34 in total

1.  A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2.

Authors:  Ryuichi Sasaoka; Hidetomi Terai; Hiromitsu Toyoda; Yuuki Imai; Ryo Sugama; Kunio Takaoka
Journal:  Biochem Biophys Res Commun       Date:  2004-06-04       Impact factor: 3.575

2.  Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2.

Authors:  Baohong Zhao; Takenobu Katagiri; Hiromitsu Toyoda; Takatora Takada; Takako Yanai; Toru Fukuda; Ung-il Chung; Tatsuya Koike; Kunio Takaoka; Ryutaro Kamijo
Journal:  J Biol Chem       Date:  2006-06-05       Impact factor: 5.157

3.  Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis.

Authors:  Vivek Joseph; Yoga Raja Rampersaud
Journal:  Spine (Phila Pa 1976)       Date:  2007-12-01       Impact factor: 3.468

4.  Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation.

Authors:  Keisuke Nakagawa; Yuuki Imai; Yoichi Ohta; Kunio Takaoka
Journal:  Bone       Date:  2007-06-29       Impact factor: 4.398

Review 5.  Regulating bone growth and development with bone morphogenetic proteins.

Authors:  Phoebe S Leboy
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

6.  Involvement of phosphodiesterase isozymes in osteoblastic differentiation.

Authors:  Shinji Wakabayashi; Takahiro Tsutsumimoto; Satoshi Kawasaki; Tetsuya Kinoshita; Hiroshi Horiuchi; Kunio Takaoka
Journal:  J Bone Miner Res       Date:  2002-02       Impact factor: 6.741

7.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

8.  Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts.

Authors:  E Gazzerro; V Gangji; E Canalis
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

9.  Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model.

Authors:  David Hannallah; Hairong Peng; Brett Young; Arvydas Usas; Brian Gearhart; Johnny Huard
Journal:  J Bone Joint Surg Am       Date:  2004-01       Impact factor: 5.284

10.  Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation.

Authors:  Derrick C Wan; Jason H Pomerantz; Lisa J Brunet; Jae-Beom Kim; Yu-Fen Chou; Benjamin M Wu; Richard Harland; Helen M Blau; Michael T Longaker
Journal:  J Biol Chem       Date:  2007-07-02       Impact factor: 5.157

View more
  28 in total

Review 1.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

2.  RNA interfering molecule delivery from in situ forming biodegradable hydrogels for enhancement of bone formation in rat calvarial bone defects.

Authors:  Minh K Nguyen; Oju Jeon; Phuong N Dang; Cong T Huynh; Davood Varghai; Hooman Riazi; Alexandra McMillan; Samuel Herberg; Eben Alsberg
Journal:  Acta Biomater       Date:  2018-06-07       Impact factor: 8.947

3.  Osteoblast maturation on microtextured titanium involves paracrine regulation of bone morphogenetic protein signaling.

Authors:  Rene Olivares-Navarrete; Sharon L Hyzy; Qingfen Pan; Ginger Dunn; Joseph K Williams; Zvi Schwartz; Barbara D Boyan
Journal:  J Biomed Mater Res A       Date:  2014-09-06       Impact factor: 4.396

4.  Light-triggered RNA release and induction of hMSC osteogenesis via photodegradable, dual-crosslinked hydrogels.

Authors:  Cong Truc Huynh; Minh Khanh Nguyen; Mantas Naris; Gulen Yesilbag Tonga; Vincent M Rotello; Eben Alsberg
Journal:  Nanomedicine (Lond)       Date:  2016-06-01       Impact factor: 5.307

5.  Effect of high glucose levels on the calcification of vascular smooth muscle cells by inducing osteoblastic differentiation and intracellular calcium deposition via BMP-2/Cbfα-1 pathway.

Authors:  Fang Liu; Hui Zhong; Jing-yuan Liang; Ping Fu; Zhi-juan Luo; Li Zhou; Rong Gou; Jun Huang
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

6.  Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration.

Authors:  Jared L Clever; Yuki Sakai; Rong A Wang; Darren B Schneider
Journal:  Am J Physiol Cell Physiol       Date:  2010-02-24       Impact factor: 4.249

7.  The factor VII-activating protease (FSAP) enhances the activity of bone morphogenetic protein-2 (BMP-2).

Authors:  Elfie Kathrin Roedel; Elisabeth Schwarz; Sandip Madhav Kanse
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

8.  The effect of noggin interference in a rabbit posterolateral spinal fusion model.

Authors:  E Klineberg; D R Haudenschild; K D Snow; S Garitty; B A Christiansen; C Acharya; S Maitra; M C Gupta
Journal:  Eur Spine J       Date:  2014-04-17       Impact factor: 3.134

9.  Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity.

Authors:  Kening Song; Carola Krause; Songting Shi; Marilyn Patterson; Robert Suto; Lovorka Grgurevic; Slobodan Vukicevic; Maarten van Dinther; Dean Falb; Peter Ten Dijke; Moulay Hicham Alaoui-Ismaili
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

10.  Advances in regenerative orthopedics.

Authors:  Christopher H Evans
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.